Document is current
Any future updates will be listed below
-
Authors
Haverman, Lotte https://orcid.org/0000-0001-7849-0562
Luijten, Michiel A. J. https://orcid.org/0000-0001-8016-2859
Blackford, Amanda L.
Absolom, Kate
Basch, Ethan M.
van Rossum, Marion A. J. https://orcid.org/0000-0002-1406-3956
Engelen, Vivian https://orcid.org/0009-0005-5811-1891
Grootenhuis, Martha A.
Velikova, Galina
Snyder, Claire https://orcid.org/0000-0001-8952-4561
-
Funding
Funding for this research was provided by:
National Institutes of Health (P30CA006973)
- License Information
-
More Information
Article History
Accepted: 21 August 2024
First Online: 3 October 2024
Declarations
:
: CS reports research funding (outside of the submitted work) from Pfizer and Genentech through her institution and personal fees from Janssen (via Health Outcomes Solutions) and Shionogi. EB reports advisory personal payments (outside of the submitted work) from Resilience Health, Navigating Cancer, Sivan, Verily, CareVive, N-Power Medicine and AstraZeneca. GV received honoraria from Pfizer, Novartis, Eisai; consultancy fees (for advisory boards) from AstraZeneca, Roche, Novartis, Pfizer, Seagen, Eisai, Sanofi; institutional grants from Pfizer, IQVIA, EORTC and speaker fees from Pfizer and Novartis (all outside the submitted work). All other authors report no competing interests.
: Secondary analysis of the included de-identified datasets was not considered human subjects research and was exempt from review by the Johns Hopkins School of Medicine Institutional Review Board and deemed permissible by the Medical Ethics Testing Committee of the Amsterdam UMC.
